Estrella Immunopharma, Inc. Share Price
ESLAEstrella Immunopharma, Inc. Stock Performance
Open $1.00 | Prev. Close $1.02 | Circuit Range N/A |
Day Range $1.00 - $1.02 | Year Range $0.73 - $3.08 | Volume 6,815 |
Average Traded $1.01 |
Estrella Immunopharma, Inc. Share Price Chart
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.
Estrella Immunopharma, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
16-Jan-26 | $1.00 | $1.00 | +0.00% |
16-Jan-26 | $1.00 | $1.00 | +4.17% |
15-Jan-26 | $0.96 | $0.96 | -9.86% |
14-Jan-26 | $1.05 | $1.06 | +13.18% |
13-Jan-26 | $0.93 | $0.94 | -15.98% |
12-Jan-26 | $1.12 | $1.12 | -7.05% |
09-Jan-26 | $1.34 | $1.21 | -15.14% |